Foster City, CA–(business wire)–Gilead Sciences, Inc. today announced a new public-private initiative with the Partnership for Advancing Health in Vietnam (HAIVN), a collaboration between Brigham and Women’s Hospital, Harvard Medical School and Beth Israel Deaconess Medical Center. . This multi-year initiative will help address barriers limiting viral hepatitis diagnosis and treatment in primary care facilities in Vietnam and the Philippines, two countries with high hepatitis B and C burdens. take an approach.
Gilead and HAIVN will work with a multi-stakeholder coalition including the national Ministry of Health, academic stakeholders including the University of the Philippines Manila (UP Manila), regional hospitals and primary care centers to support this pilot program. . The program’s focus is on a person-centred approach in training non-specialist, community-based health care providers in viral hepatitis prevention and management, providing education, screening, diagnosis, and treatment of hepatitis B and C. Incorporate care coordination into regular patient visits. population at risk. Gilead and her HAIVN will also aim to strengthen the primary health care system, including referral and counter-referral systems, to strengthen collaboration between specialists and primary care. The two organizations will publish the outcomes and lessons learned from the initiative and contribute to a better understanding of appropriate public health approaches to improve person-centred, community-based management of viral hepatitis.
“This collaboration will provide evidence to support a shift from the current scarcity and over-reliance on specialists to a broader group of primary care clinicians, while strengthening primary health care systems and diagnosing viral hepatitis. It expands national capacities to manage, manage and treat Duong, MD, MPH, Director of the Harvard Medical School Program on Global Primary Care and Social Transformation and Physician at Brigham and Women’s Hospital. “Through this innovative initiative with Gilead, we build on the foundation HAIVN has laid to apply a new patient-centered, community-based model to hepatitis care and treatment. ”
This initiative supports the national priorities of Vietnam and the Philippines. Both governments are committed to strengthening primary care and controlling hepatitis. Decrease in mortality in addition to the development of world preventive measures.1 However, despite significant advances in biomedical technology and the management of viral hepatitis, the implementation of best practices and access to diagnosis and treatment in both countries remains severely limited and inconsistent. At the current pace, Vietnam and the Philippines are not expected to meet his WHO target by 2050.
“This approach has great potential for application in many other disease areas and in low- and middle-income countries where specialists are scarce. ” “This initiative goes beyond a proof-of-concept to eradicate viral hepatitis and strengthen health care systems. It demonstrates the potential to have a meaningful impact on achieving Sustainable Development Goal 3. ”
Hepatitis B and C cause chronic disease in hundreds of millions of people worldwide and together are the most common causes of cirrhosis, liver cancer and viral hepatitis-related death. An estimated 354 million people worldwide have been infected with her hepatitis B or C, making testing and treatment out of reach for most.2 In Vietnam, about 7.8 million people are infected with hepatitis B and more than 900,000 people are infected with hepatitis C, out of a population of 97 million. Based on his 2020 estimates from the CDA Foundation’s Polaris database, only 30% of Vietnamese were diagnosed with hepatitis B. 3% treated. For hepatitis C, only 14% of cases are diagnosed and 7% are treated.3 In the Philippines, more than 10 million people are infected with hepatitis B, nearly 450,000 are infected with hepatitis C, 5% are diagnosed with hepatitis B, and 1 receive treatment. %, 23% were diagnosed with hepatitis C, and only 1% received treatment. 3
About the Sustainable Development Goals
The 17 Sustainable Development Goals (SDGs) were adopted by United Nations (UN) Member States in 2015 as part of the 2030 Agenda for Sustainable Development. They are a call to action by all nations to unite in a global partnership to ensure peace and prosperity for people and the planet. SDG 3 Good health and well-being for all is one of his SDGs that Gilead supports to improve global health and sustainable development. SDG 3 consists of several goals, including combating epidemics, achieving universal health coverage, increasing healthcare funding, and supporting health workers in developing countries. For more information on the SDGs that Gilead supports, please visit: www.gilead.com.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company with more than 30 years of pursuing and achieving medical breakthroughs with the goal of creating a healthier world for all. The company is committed to developing innovative medicines for the prevention and treatment of life-threatening diseases such as HIV, viral hepatitis and cancer. Headquartered in Foster City, California, Gilead has operations in more than 35 countries around the world.
Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its affiliates.
For more information about Gilead, please visit the company’s website at: www.gilead.com follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
1 WHO Global Health Sector Strategy on Viral Hepatitis 2016-201: Towards Ending Viral Hepatitis https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf
2 https://www.who.int/health-topics/hepatitis#tab=tab_1
3 CDAF https://cdafound.org/.
